|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Lymphoma | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Lymphoma, B-Cell | |||||
| Lymphoma, Non-Hodgkin | |||||
| 3 | More general conditions related to this trial | ||||
| Immune System Diseases | |||||
| Immunoproliferative Disorders | |||||
| Lymphatic Diseases | |||||
| Lymphoproliferative Disorders | |||||
| Neoplasms | |||||
| Neoplasms by Histologic Type | |||||
| 4 | Interventions listed in this trial | ||||
| denileukin diftitox | |||||
| rituximab | |||||
| flow cytometry | |||||
| immunoenzyme technique | |||||
| laboratory biomarker analysis | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Interleukin-2 | |||||
| 6 | More general drug interventions related to this trial | ||||
| Analgesics | |||||
| Analgesics, Non-Narcotic | |||||
| Antineoplastic Agents | |||||
| Antirheumatic Agents | |||||
| Central Nervous System Agents | |||||
| Immunologic Factors | |||||
| Peripheral Nervous System Agents | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Sensory System Agents | |||||
| Therapeutic Uses | |||||
| 7 | Sponsors listed in this trial | ||||
| North Central Cancer Treatment Group | |||||
| National Cancer Institute (NCI) | |||||